In light of these properties and its GLP‐1 activity in regulating insulin secretion, in 2005, exendin‐4 (marketed as exenatide) became the first peptide approved by the FDA for the treatment of type II diabetes (Davidson et al. 2005). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.